A medication that quiets an overactive immune system cut inflammation in people with Down syndrome and improved painful skin conditions, a phase 2 trial published on 17 November 2026 found — but every participant got the drug, so the cognitive gains remain unproven.
Tofacitinib, a JAK inhibitor that blocks the signals driving immune responses, cut inflammation in a trial run by the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz. Results appeared in Cell Reports Medicine, and CU Anschutz announced them on 18 November.
Safety outcomes hit the benchmarks set before the trial began. The authors characterize the drug’s tolerability as comparable to what is observed in the wider population.
Treatment lowered interferon scores, cytokine scores and inflammation-linked metabolites — including quinolinic acid, which has known neurotoxic effects — without overt immune suppression, according to the published abstract.
Participants, adolescents and adults with Down syndrome who also had inflammatory skin conditions, took tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks. The clearest clinical benefits were in hidradenitis suppurativa and alopecia areata, assessed with standardized clinical scores and dermatology quality-of-life measures.
“We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions. The results of this study lay the groundwork for future clinical trials that could address a broader range of conditions associated with Down syndrome,” said senior author Joaquín Espinosa, executive director of the Crnic Institute and professor of pharmacology at CU Anschutz, per Contemporary Pediatrics.

Why the Immune System Was the Target
Down syndrome is caused by an extra copy of chromosome 21, which carries genes for several interferon receptors — molecules that regulate immune responses. Earlier work by the Crnic Institute established that this genetic change drives chronically elevated interferon signaling and widespread immune dysregulation, the rationale for testing whether dialing it down could help.
“One of the most exciting findings is that we could bring several abnormal inflammatory markers closer to the levels observed in people without Down syndrome,” said Angela Rachubinski, first author of the study, in the announcement carried by BioSpace.
Multi-omics analyses of gene expression, circulating proteins and metabolites showed the drug modified specific inflammatory pathways rather than shutting the immune system down.
Importantly, this medication appears to calm an overactive immune system without weakening normal immune defenses in people with Down syndrome, which may explain its encouraging safety profile. Rachubinski said
The Catch: No Placebo Group
The trial was open-label and single-arm — no masking, no placebo — registered as NCT04246372. The authors themselves call the efficacy findings exploratory, and the abstract states this directly.

Participants performed better on selected tests of attention, memory, vocabulary and behavior, and some participant- and caregiver-reported well-being measures improved.
But because everyone received the drug, practice effects and other factors cannot be separated from a treatment effect, as CASRAI’s analysis notes.
“The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition,” said Lina Patel, a study co-author and professor of psychiatry at CU Anschutz.
What this study establishes is an opportunity to ask more precise questions about which improvements may be due to treatment, while continuing to prioritize participant safety.
Lina Patel, professor of psychiatry, CU Anschutz
The safety result also has limits. The researchers warn that the well-documented hazards of JAK inhibitors remain in force, and bigger trials will be required to evaluate how the drugs fare over the long term in people with Down syndrome.
Tofacitinib is not approved specifically for Down syndrome, and the study does not establish a general treatment recommendation, as JournalArta reports.
Second Trial Targets Regression Disorder
The paper now presents the complete findings from a trial whose preliminary results the same team released back in 2024. In August 2024, Medical Xpress covered an early look at the first participants, which reported improvements in skin pathology — most strikingly in alopecia areata — and inflammatory markers returning toward the normal range, according to CASRAI’s timeline.
By comparing the trial findings with those earlier datasets, the team identified biological changes that may respond to JAK inhibition and biomarkers for monitoring treatment effects. The researchers call for randomized, placebo-controlled studies to evaluate clinical benefits, optimal participant selection and longer-term safety.
A follow-up study targeting Down Syndrome Regression Disorder — marked by an abrupt decline in neurological function — is now underway, and its findings are anticipated in 2027.
“As the mother of my amazing 23-year-old daughter Sophia, it is deeply moving to see the Crnic Institute's groundbreaking research, which GLOBAL supported from the beginning, lead to promising clinical results,” said Michelle Sie Whitten, president and CEO of the Global Down Syndrome Foundation. She added gratitude to the NIH INCLUDE Project and Espinosa’s team for work aimed at longer, healthier lives.
Funding came from the NIH INCLUDE Project, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation and the Ruth E. Olleman Trust, according to the study record.